Toggle light / dark theme

Today, we are delighted to announce that we have launched a new crowdfunding campaign on Lifespan.io: the NAD+ Mouse Project by Dr. David Sinclair and his team at Harvard Medical School.

NAD+ is a vitally important molecule that is found in every cell in your body and is involved in DNA repair, tissue growth, nutrient sensing and metabolism, cell-to-cell signaling, and many other cellular processes. Quite simply, without NAD+, cells would not work and life would be impossible. If you would like to learn more about NAD+ and its role in aging, check out our articles here, here, and here.

Read more

On the new article by Prof Dr S. Olshansky published in JAMA, advising to focus on healthspan extension not on lifespan extension. No, I personally believe that we can still focus on lifespan extension. We could obtain indefinite healthy life extension by different methods of rejuvenation because the rejuvenation process eliminates the main reason for sickness ie the aging diseases and renders us healthy again! And also only through indefinite life extension we could close the gap of tens of years between the lifespan in different social and ethnic groups (Lens-Pechakova, Rejuvenation Res. 2014 Apr;17:239–42)


Clinicians, scientists and public health professionals should proudly “declare victory” in their efforts to extend the human lifespan to its very limits, according to University of Illinois at Chicago epidemiologist S. Jay Olshansky.

In an article published in the Journal of the American Medical Association, Olshansky writes that the focus should shift to compressing the “red zone” — the time at the end of life characterized by frailty and disease, and extending the “healthspan” — the length of time when a person is alive and healthy.

Read more

Today, we have an update from the MitoSENS team over at the SENS Research Foundation. As some of you may recall, MitoSENS was the first project we hosted on our research fundraising platform Lifespan.io back in August 2015. The project was successfully funded and raised $46,128, which was 153% of the funds needed. The extra funds were used to increase the scope of the project, which resulted in a paper being published in the prestigious Oxford Journal.

Since then, the team has been busy working on transferring the other mitochondrial genes to the nucleus, and they have given us an update to let everyone know how things are progressing at the lab. Dr. Matthew “Oki” O’Connor had the following to say about progress and the future.

Hi, everyone! Time for another exciting mito update. This time, we’ve got 2 teasers for you. The first is that we’re preparing a story about a new trick that we’ve discovered to improve the allotopic expression of mito genes. We’re still confirming that we’re 100% sure that we’re right before writing up the manuscript and making an announcement, but we’re very close. Yes, that means we’re getting it to work on more genes. Stay tuned!

Read more

SpaceX’s CEO shrugs off 20 years of NASA research.


SORRY, ELON. To be ready for human occupants, Elon Musk has long called Mars a “fixer-upper of a planet.” But according to a new NASA-sponsored study, a better description might be a “tear-down.” The scientists behind that project say it’s simply not possible to terraform Mars — that is, change its environment so that humans can live there without life support systems — using today’s technology.

BUILDING AN ATMOSPHERE. Mars has a super thin atmosphere; a human unprotected on the surface of Mars would quickly die, mostly because there’s not enough atmospheric pressure to prevent all your organs from rupturing out of your body (if you survived a little longer, you could also suffocate from lack of oxygen, freeze from low temperatures, or get fried from too much ultraviolet radiation).

This study, published Monday in the journal Nature Astronomy, considers how difficult it would be to increase the atmospheric pressure on the Red Planet enough so that humans can walk on Mars’s surface without a pressurized suit and, ideally, without a breathing apparatus.

Read more

Alzheimer’s disease (AD) is a neurodegenerative disease with characterization of deficits in progressive memory loss, cognitive and behaviour functions. Mild cognitive impairment (MCI) is a predromal stage of AD, displaying cognitive deficit but neither marked functional impairment nor satisfying established clinical criteria for dementia or probable AD. However, not all MCI patients may eventually progress to AD (progressive MCI, pMCI)https://doi.org/10.1016/j.nicl.2013.10.

(2014)." href="https://www.nature.com/articles/s41598-018-31794-8#ref-CR2" id="ref-link-section-d1856e5935"]2, and some remain unchanged (stable MCI, sMCI), or are recovered from. Therefore, differential diagnosis of MCI types and earlier diagnosis of AD and prediction of disease evolution are difficult

Read more

New research published in PLOS One has found that virtual reality use impairs physical and cognitive performance while trying to balance.

“I became interested in this topic because virtual reality headsets have recently become widely available, with great potential to make rehabilitation more enjoyable and varied for patients,” said study author Steven M. Peterson of the University of Michigan, Ann Arbor.

“While many studies have explored upper-limb activities, I wanted to understand how immersive and mentally challenging a virtual reality headset is when the user is walking around and not seated. We decided to test the realism of virtual reality by looking for stress at high heights because just the perception of heights can affect how people walk and how cautious they are.”

Read more

Promising approach to deliver personalized and non-invasive brain stimulation in clinical settings.


BrainsWay’s Brain Stimulation Device Receives FDA Approval to Treat Obsessive-Compulsive Disorder (IEEE Spectrum):

In 2013, Jerusalem-based BrainsWay began marketing a new type of brain stimulation device that uses magnetic pulses to treat major depressive disorder.

Now, thanks to positive results in a study of 100 patients, the company has received approval from the U.S. Food and Drug Administration (FDA) to market the device for a second psychiatric condition—obsessive-compulsive disorder (OCD) …

Read more